newsfilter
← Latest News
Business Wire·

OSE Immunotherapeutics Announces: Positive Phase 3 Data from its Cancer Vaccine in Lung Cancer Patients with Resistance to Previous Immunotherapy Published in Annals of Oncology

Leading medical journal highlights peer-reviewed, randomized phase 3 clinical results with Tedopi® off-the-shelf T-cell epitope-based cancer vaccine monotherapy compared to chemotherapy in advanced non-small cell